Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;107:1424-1432
Published online before print March 3, 2003, doi: 10.1161/01.CIR.0000055319.94801.FC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
107/10/1424    most recent
01.CIR.0000055319.94801.FCv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heineke, J.
Right arrow Articles by Wollert, K. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heineke, J.
Right arrow Articles by Wollert, K. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrow Structure
Right arrow Physiological and pathological control of gene expression
Right arrowRelated Article

(Circulation. 2003;107:1424.)
© 2003 American Heart Association, Inc.


Basic Science Reports

Downregulation of Cytoskeletal Muscle LIM Protein by Nitric Oxide

Impact on Cardiac Myocyte Hypertrophy

Jörg Heineke, MD; Tibor Kempf, MD; Theresia Kraft, PhD; Andres Hilfiker, PhD; Henning Morawietz, PhD; Robert J. Scheubel, MD; Pico Caroni, PhD; Suzanne M. Lohmann, MD, PhD; Helmut Drexler, MD; Kai C. Wollert, MD

From the Departments of Cardiology and Angiology (J.H., T. Kempf, A.H., H.D., K.C.W.) and Molecular and Cellular Physiology (T. Kraft), Hannover Medical School, Hannover, Germany; the Institute of Pathophysiology (H.M.) and the Department of Cardiothoracic Surgery (R.J.S.), University of Halle-Wittenberg, Halle-Wittenberg, Germany; the Friedrich-Miescher Institute (P.C.), Basel, Switzerland; and the Institute of Clinical Biochemistry and Pathobiochemistry (S.M.L.), University of Würzburg, Würzburg, Germany.

Correspondence to Priv-Doz Dr med Kai C. Wollert, Abteilung Kardiologie und Angiologie, Medizinische Hochschule Hannover, Carl-Neuberg Straße 1, 30625 Hannover, Germany. E-mail wollert.kai{at}mh-hannover.de

Background— In chronic heart failure, myocardial expression of the inducible isoform of nitric oxide (NO) synthase (NOS2) is enhanced, leading to a sustained production of NO. We postulated that NO modulates expression of genes in cardiac myocytes that may be functionally important in the context of cardiac hypertrophy and failure.

Methods and Results— As revealed by cDNA expression array analyses, the NO donor SNAP, which has been shown previously to inhibit agonist-induced cardiac myocyte hypertrophy, downregulates expression of the cytoskeleton-associated muscle LIM protein (MLP) in endothelin-1 (ET-1)–stimulated neonatal rat cardiac myocytes. Northern blotting and immunoblotting experiments confirmed this finding and established that SNAP negatively controls MLP mRNA (-49%, P<0.01) and protein (-52%, P<0.01) abundance in ET-1–treated cardiomyocytes via cGMP-dependent protein kinase and superoxide/peroxynitrite-dependent signaling pathways. Treatment of cardiac myocytes with IL-1ß and IFN-{gamma} downregulated MLP expression levels via induction of NOS2. Moreover, expression levels of NOS2 and MLP were inversely correlated in the failing human heart, indicating that NOS2 may regulate MLP abundance in vitro and in vivo. Antisense oligonucleotides were used to explore the functional consequences of reduced MLP expression levels in cardiac myocytes. Like SNAP, antisense downregulation of MLP protein expression (-52%, P<0.01) blunted the increases in protein synthesis, cell size, and sarcomere organization in response to ET-1 stimulation. Conversely, overexpression of MLP augmented cell size and sarcomere organization in cardiac myocytes.

Conclusions— NO negatively controls MLP expression in cardiac myocytes. Because MLP is necessary and sufficient for hypertrophy and sarcomere assembly, MLP downregulation may restrain hypertrophic growth in pathophysiological situations with increased cardiac NO production.


Key Words: nitric oxide • cytoskeleton • myocytes • hypertrophy


Related Article:

NO Balance: Regulation of the Cytoskeleton in Congestive Heart Failure by Nitric Oxide
Cornel Badorff and Stefanie Dimmeler
Circulation 2003 107: 1348-1349. [Full Text]



This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. W. Donker, J. G. Maessen, F. Verheyen, F. C. Ramaekers, R. L. H. M. G. Spatjens, H. Kuijpers, C. Ramakers, P. M. H. Schiffers, M. A. Vos, H. J. G. M. Crijns, et al.
Impact of acute and enduring volume overload on mechanotransduction and cytoskeletal integrity of canine left ventricular myocardium
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2324 - H2332.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Thai, L. Castellano, E. Juneman, H. Phan, R. Do, M. A. Gaballa, and S. Goldman
Pretreatment With Angiotensin Receptor Blockade Prevents Left Ventricular Dysfunction and Blunts Left Ventricular Remodeling Associated With Acute Myocardial Infarction
Circulation, October 31, 2006; 114(18): 1933 - 1939.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Fiedler, R. Feil, F. Hofmann, C. Willenbockel, H. Drexler, A. Smolenski, S. M. Lohmann, and K. C. Wollert
cGMP-dependent Protein Kinase Type I Inhibits TAB1-p38 Mitogen-activated Protein Kinase Apoptosis Signaling in Cardiac Myocytes
J. Biol. Chem., October 27, 2006; 281(43): 32831 - 32840.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. Hilfiker-Kleiner, U. Landmesser, and H. Drexler
Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A56 - A66.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. E. Murdoch, M. Zhang, A. C. Cave, and A. M. Shah
NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure
Cardiovasc Res, July 15, 2006; 71(2): 208 - 215.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
R. Hataishi, A. C. Rodrigues, J. G. Morgan, F. Ichinose, G. Derumeaux, K. D. Bloch, M. H. Picard, and M. Scherrer-Crosbie
Nitric oxide synthase 2 and pressure-overload-induced left ventricular remodelling in mice
Exp Physiol, May 1, 2006; 91(3): 633 - 639.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Kempf, M. Eden, J. Strelau, M. Naguib, C. Willenbockel, J. Tongers, J. Heineke, D. Kotlarz, J. Xu, J. D. Molkentin, et al.
The Transforming Growth Factor-{beta} Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury
Circ. Res., February 17, 2006; 98(3): 351 - 360.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Vornanen, M. Hassinen, H. Koskinen, and A. Krasnov
Steady-state effects of temperature acclimation on the transcriptome of the rainbow trout heart
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R1177 - R1184.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. M. Shah
Divergent roles of endothelial nitric oxide synthase in cardiac hypertrophy and chamber dilatation?
Cardiovasc Res, June 1, 2005; 66(3): 421 - 422.
[Full Text] [PDF]


Home page
HypertensionHome page
G. W. Booz
Putting the Brakes on Cardiac Hypertrophy: Exploiting the NO-cGMP Counter-Regulatory System
Hypertension, March 1, 2005; 45(3): 341 - 346.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Heineke, H. Ruetten, C. Willenbockel, S. C. Gross, M. Naguib, A. Schaefer, T. Kempf, D. Hilfiker-Kleiner, P. Caroni, T. Kraft, et al.
Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc
PNAS, February 1, 2005; 102(5): 1655 - 1660.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. Fiedler and K. C Wollert
Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes
Cardiovasc Res, August 15, 2004; 63(3): 450 - 457.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Tongers, B. Fiedler, D. Konig, T. Kempf, G. Klein, J. Heineke, T. Kraft, S. Gambaryan, S. M Lohmann, H. Drexler, et al.
Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes
Cardiovasc Res, August 15, 2004; 63(3): 545 - 552.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
H.-R. Liu, L. Tao, E. Gao, B. L Lopez, T. A Christopher, R. N Willette, E. H Ohlstein, T.-L. Yue, and X.-L. Ma
Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion
Cardiovasc Res, April 1, 2004; 62(1): 135 - 144.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R. B. Pilz and D. E. Casteel
Regulation of Gene Expression by Cyclic GMP
Circ. Res., November 28, 2003; 93(11): 1034 - 1046.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Badorff and S. Dimmeler
NO Balance: Regulation of the Cytoskeleton in Congestive Heart Failure by Nitric Oxide
Circulation, March 18, 2003; 107(10): 1348 - 1349.
[Full Text] [PDF]